Skip to main content
. 2013 Dec 23;8(12):e83607. doi: 10.1371/journal.pone.0083607

Table 4. Type of EGFR mutations observed in our series.

SANGER
Type of mutation Ex Num cases a Predicted role for TKI treatment References
G719A 18 1 Response [1,2,15,17]
Exon 19 deletions 19 10 Response [1,2,8,13,15-17]
L858R 21 3 Response [1,14-16]
T790M 20 1 Resistance [19-21]
NGS
Type of mutation Ex Num cases b Predicted role for TKI treatment References
G719A 18 1 Response [1,2,15,17]
Exon 19 deletions 19 14 Response [1,2,8,13,15-17]
L858R 21 5 Response [1,14-16]
P772S 20 1 Response (Putative) [18]
T790M 20 1 Resistance [19-21]
R831H 21 1 Resistance [22]
F795S 20 1 Undefined (reported in CRC and SCC of the oral cavity) [62,65]
T785I 20 1 Undefined (reported in NSCLC) [63,66]
V845M 21 1 Undefined (reported in adrenocortical carcinoma) [64]
P691T, K708N, G721W, S752F, D807G 18, 19, 20, 21 1 each Mutations not previously described -

aIn one case double mutations were observed; bin six cases double/multiple mutations were observed. TKI, tyrosine kinase inhibitor; CRC, colorectal carcinoma; SCC, squamous cell carcinoma; NSCLC non small cell lung carcinoma.